Background And Aim: Percutaneous occlusion of patent ductus arteriosus (PDA) has become increasingly attractive with the evolution of devices and techniques. This study aimed to report the total experience of a novel arterial occlusion device (Duct Occlude pfm) and Amplatzer.
Methods: A descriptive study which selected non-randomized pediatric patients with patent ductus arteriosus (PDA) was performed between May 2007 to February 2012 on 99 children aged 8 months to 16 years who underwent attempted closure of PDA. Transcatheter occlusion was attempted in all the cases of coil through a 4-5 F and for Amplatzer 6-7 F delivery catheter.
Findings: Devices were successfully deployed in 98% of patients. Amplatzer was used for thirty four patients (34%) due to medium to large PDA and coil was selected for sixty five patients (66%) due to small to medium size PDA.One day after the procedure, complete occlusion was accomplished in 42 (69%) out of 61 patients in whom the detachable coil device had been used on color-flow Doppler echocardiography. Embolization of a coil occurred on 1 occasion.
Conclusion: METHODS of detachable coil and Amplatzer type occlusion system compares favorably with other methods of transcatheter PDA occlusion.
Download full-text PDF |
Source |
---|
Front Vet Sci
December 2024
Department of Veterinary Clinical Science, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Seoul, Republic of Korea.
Introduction: The objective of this study is to analyze the morphology and measurement dimensions of patent ductus arteriosus (PDA) based on computed tomography images.
Methods: The present study retrospectively evaluated computed tomography angiography data from 25 client-owned dogs diagnosed with PDA. PDA was reconstructed based on the central axis and the minimum diameter, ampulla diameter, angle, ampulla cross-section area, and length values were measured at specific measurement sites.
J Cardiothorac Surg
January 2025
Department of Cardiovascular Surgery of The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, Zhejiang, 310000, China.
Interventional occlusion of Patent ductus arteriosus (PDA) is generally efficacious and complications such as delayed occluder displacement are infrequent. Herein, we report a case of 24-year-old female with a history of unsuccessful PDA closures, who subsequently experienced delayed occluder displacement into the left main pulmonary artery. Despite numerous unsuccessful catheter-based interventions, thoracic endovascular aortic repair (TEVAR) was successfully executed.
View Article and Find Full Text PDFUnlabelled: Hemodynamically significant patent ductus arteriosus (hs-PDA) in very low birth weight (VLBW) infants continues to be an issue of research regarding the timing of treatment and which would be the most appropriate drug.
Objective: To assess the outcome of prolonged treatment with paracetamol in the closure of hemodynamically significant patent ductus arteriosus in preterm newborns.
Patients And Method: Retrospective study in VLBW infants with echocardiographic and clinical diagnosis of hs-PDA who received treatment with intravenous paracetamol at 15 mg/kg every 6 hours for 6 days.
Cardiovasc Ther
January 2025
Department of Pediatric Cardiology Saarland University Medical Center, Homburg 66421, Germany.
The objective of this study is to evaluate the clinical application and primary outcome of transcatheter embolization using Amplatzer™ Vascular Plug (AVP) Type 2 and Type 4 in different congenital cardiovascular malformations. This is a single-center retrospective observational cohort study. We analyzed clinical and imaging data of 36 patients retrospectively who received transcatheter embolizations of the following malformations using AVP: systemic-to-pulmonary collateral arteries (SPCA), patent ductus arteriosus (PDA), ventricular septal defects (VSD), and aberrant pulmonary sequestration arteries (PSA).
View Article and Find Full Text PDFIntroduction Respiratory distress syndrome (RDS) is a leading cause of morbidity and mortality among preterm infants, necessitating effective treatment strategies. This study compared the efficacy of Beractant (SURVANTA®) to Poractant alfa (CUROSURF®) in treating RDS in preterm infants admitted to Tawam Hospital in the UAE. Methodology This retrospective study included preterm infants from 23+0 to 36+6 weeks of gestation with a diagnosis of RDS and treatment by Beractant or Poractant alfa within 48 hours of life between January 2020 and March 2023.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!